---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016979"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:30.535087+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma signs LOI to acquire automotive supplier DCS for $30M; DCS had $200M+ revenue in FY2025

## Summary
- Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).
- DCS is a tier-one auto supplier with 310 patents, 11 global facilities, serving 150+ vehicle platforms across major OEMs.
- Management from Lakewood & Company (100+ years auto experience) to bolster DCS leadership; deal subject to due diligence and audit.
- RBW Capital Partners is exclusive financial advisor; Dawson James Securities will provide brokerage services for the acquisition.
- Aspire plans to become a diversified, high-revenue enterprise; no definitive agreement executed yet and no assurance of completion.

## SEC filing metadata
- accession: 0001493152-26-016979
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226016979/0001493152-26-016979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226016979/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016979
- JSON: https://secwatch.observer/filing/0001493152-26-016979.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.